Pancreatic cancer is one of the most lethal cancers. Preclinical studies have shown adaptive resistance to Raf/MEK/ERK and PI3K/Akt pathway inhibition. We identify common protein expression alterations associated with adaptive resistance to MEK and PI3K kinase inhibition in KRas-mutant pancreatic cancer cells.